West Pharmaceutical Services, Inc. (NYSE:WST) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give West an average rating of “Moderate Buy” from 12 firms (7 buys, 4 holds, 1 strong buy) with a one‑year consensus target of $315.67.
• West posted a Q1 beat (EPS $2.13 vs $1.68 est.; revenue $844.9M, +21% YoY) and raised FY2026 guidance to $8.40–$8.75, prompting analyst upgrades and positive sentiment.
• The board authorized a $1.00 billion share repurchase (up to ~5.6% of shares) and declared a quarterly dividend of $0.22 (annualized $0.88, ~0.3% yield); institutional investors own about 93.9% of the stock.

Shares of West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $315.6667.

A number of analysts recently issued reports on the company. Evercore reaffirmed an "outperform" rating on shares of West Pharmaceutical Services in a research report on Friday. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Zacks Research downgraded West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 14th. Barclays boosted their price target on West Pharmaceutical Services from $265.00 to $275.00 and gave the stock an "equal weight" rating in a research report on Tuesday, April 14th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in West Pharmaceutical Services by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier's stock worth $2,545,899,000 after buying an additional 388,144 shares during the last quarter. State Street Corp increased its position in West Pharmaceutical Services by 2.1% during the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier's stock worth $715,884,000 after buying an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership increased its position in West Pharmaceutical Services by 2.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier's stock worth $784,259,000 after buying an additional 79,481 shares during the last quarter. Geode Capital Management LLC increased its position in West Pharmaceutical Services by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier's stock worth $512,250,000 after buying an additional 11,962 shares during the last quarter. Finally, Generation Investment Management LLP boosted its holdings in shares of West Pharmaceutical Services by 60.0% during the fourth quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier's stock worth $429,733,000 after acquiring an additional 585,855 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $305.31 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The stock's 50-day simple moving average is $253.11 and its 200 day simple moving average is $262.29. The company has a market cap of $21.57 billion, a P/E ratio of 40.82, a P/E/G ratio of 2.99 and a beta of 1.15. West Pharmaceutical Services has a 52-week low of $202.79 and a 52-week high of $322.34.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.West Pharmaceutical Services's quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services will post 8.63 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services's payout ratio is 11.76%.

West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase program on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Beat-and-raise: West delivered a sizable Q1 beat and raised FY2026 EPS to $8.40–8.75 and Q2 EPS to $2.05–2.12, citing strong demand for proprietary injectable components. This directly improves forward earnings visibility and underpins the rally. West Reports First-Quarter 2026 Results
• Positive Sentiment: HVP and execution callout: Deep-dive coverage highlights that growth was led by high‑value components and operational execution — factors that support margin expansion and recurring revenue from injectable drug trends. WST Q1 Deep Dive: High-Value Components and Operational Execution Drive Outperformance
• Positive Sentiment: Analyst upgrade: TD Cowen added a Buy on WST, which can attract new buyer interest and lend support to the shares after the beat-and-raise. West Pharmaceutical Services (WST) Gets a Buy from TD Cowen
• Positive Sentiment: Positive analyst writeups: Multiple analyst notes and commentary (Seeking Alpha, Zacks) point to durable demand, margin improvement and upside to estimates — reinforcing the upbeat investor narrative. West Pharmaceutical: A High-Quality Beat-And-Raise With More Upside Ahead
• Neutral Sentiment: Earnings details & readouts: The full earnings call transcript and slide deck provide management color on portfolio mix, capacity plans and timing of customer programs — useful for modeling but not an immediate catalyst by itself. West Pharmaceutical Services, Inc. NYSE: WST Q1 2026 Earnings Call Transcript
• Negative Sentiment: Short-term pullback risk: Despite the strong fundamentals, the stock traded lower today — likely profit‑taking after a recent run toward the 52‑week high and because WST carries a premium valuation (PE ~45). Expect near‑term volatility as traders digest the beat, upgrade and elevated expectations.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.